Stockscreener 앱 받기
31.06
1.40%
0.43
시장 영업 전:
30.06
-1.00
-3.22%
Tyra Biosciences Inc 주식(TYRA)의 최신 뉴스
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TYRA|Tyra Biosciences Inc|Price:31.802|Chg%:+1.172 - TradingKey
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TYRA|Tyra Biosciences Inc|Price:31.060|Chg%:+0.430 - TradingKey
TradingKey - TradingKey
Tyra Biosciences, Inc. Revenue Breakdown – NASDAQ:TYRA - TradingView
Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC - Traders Union
Tyra Biosciences (TYRA) Q4 2025 earnings summary - Quartr
Tyra Biosciences (TYRA) Jefferies London Healthcare Conference 2025 Summary - Quartr
Tyra Biosciences (TYRA) Proxy filing Summary - Quartr
Tyra Biosciences pursues new treatment strategies for urologic cancers - Traders Union
Behavioral Patterns of TYRA and Institutional Flows - Stock Traders Daily
Tyra Biosciences (TYRA) Bank of America Global Healthcare Conference 2026 Summary - Quartr
Tyra Biosciences (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D Investment; Stock Dips SlightlyProfit Guidance Range - dars.gov.et
Price to earnings forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
Enterprise value to EBIT forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Price to sales forward of Tyra Biosciences, Inc. – BOATS:TYRA - TradingView
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Tyra Biosciences Inc. (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline Progress Drives Positive SentimentPost-Earnings Drift - dars.gov.et
Non Muscle Invasive Bladder Cancer Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Enterprise value to EBITDA forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Insider Monkey
Bladder Cancer Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Tyra Biosciences (TYRA) Holds Slight Gains as Resistance Level NearsWeekly Profile - dars.gov.et
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark - marketscreener.com
TYRA Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineLow Growth Earnings - dars.gov.et
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark - marketscreener.com
(TYRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 2500 Value Benchmark - marketscreener.com
10 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Tyra Biosciences, Inc.(NasdaqGS:TYRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 2000 Value Benchmark - marketscreener.com
Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com - Investing.com Nigeria
Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks - Moomoo
TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026 - Stock Titan
Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA) - TradingView
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In? - Sahm
TYRA Forecast — Price Target — Prediction for 2027 - TradingView
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
JonesTrading Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $56 - 富途牛牛
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight - Yahoo Finance
Tyra Biosciences (TYRA) Slips 2.58%: Support Level in Focus After Weekly DeclineReversal Trade - dars.gov.et
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA) - The Globe and Mail
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Institutional Confidence - TradingKey
Tyra Biosciences Inc (TYRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TYRA PE Ratio & Valuation, Is TYRA Overvalued - Intellectia AI
TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
1.97%
0.83%
자본화:
|
볼륨(24시간):